Company intelligence / Profile preview

Minghui Pharmaceutical (Hangzhou) Ltd

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

Minghui is a clinical-stage biotech with a focus on oncology and immunology, advancing multiple innovative antibody-drug conjugates, bispecific antibodies, and JAK inhibitors. Recent clinical results for MHB039A (PD-1 x VEGF bispecific) show promising antitumor activity in heavily pretreated solid tumor patients, especially non-small cell lung cancer (NSCLC). MHB088C (B7-H3 ADC) has demonstrated robust efficacy and safety in >300 patients, with ongoing Phase III trials in small cell lung cancer (SCLC).

Therapeutic areas: OncologyDermatologyImmunology
Modalities: Antibody-drug conjugateBispecific monoclonal antibodySmall moleculeTopical cream
Industry: Biotech

Partnerships

Qilu Pharmaceutical (exclusive Greater China rights to MHB088C)

Beyond the preview

Go deeper on Minghui Pharmaceutical (Hangzhou) Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Minghui Pharmaceutical (Hangzhou) Ltd.

Explore the full profile